Reference entry · Synthetic pentadecapeptide
BPC-157
Also known as: Body Protection Compound-157 · pentadecapeptide BPC
- Class
- Synthetic pentadecapeptide
- Size
- 15 amino acids
- Primary targets (literature)
- Multi-pathway (GI, angiogenesis, NO-system literature)
- Regulatory context
- Not an FDA-approved drug. Catalog BPC-157 is research-use-only material distinct from any approved pharmaceutical product.
Overview
BPC-157 is a synthetic pentadecapeptide sequence derived from gastric-juice protein fragments. It is among the most discussed catalog peptides in connective-tissue and gastrointestinal preclinical literature — with a large but investigator-concentrated rodent bibliography.
Mechanism in research literature
Published models explore interactions with growth-factor signaling, nitric-oxide pathways, and angiogenesis in rodent tissue — without a single dominant mechanism established across independent labs.
Common research focus areas
- Tendon and ligament fibroblast models
- Gastrointestinal mucosal injury in rodents
- Angiogenesis and blood-vessel research
- Material identity verification for catalog supply
Full literature roundup
Read the cited research summary
A pentadecapeptide studied extensively in rodent models. What the preclinical literature reports — and what remains unestablished in humans.
BPC-157 research roundup · 7 minEvaluate catalog material
- COA literacy — read batch documentation before comparing vendors.
- Peptide identity testing — why sequence confirmation matters beyond purity %.
- How we vet sources — our score methodology for recommended vendors.